Tracon raises $36M in a downsized IPO

Cancer drug developer Tracon Pharmaceuticals pulled in $36 million in an IPO, pricing well below its expected range as it works to get its top drug into late-stage trials. The San Diego biotech sold 3.6 million shares at $10 each, far off from its early plans of pricing between $12 and $14. With the proceeds, Tracon will fund the Phase II development of TRC105, an antibody that blocks a protein essential to the formation of new blood cells, thereby starving tumors and killing cancer. More

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.